SINTX TECHNOLOGIES INC (SINT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$1.63+5.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · SINT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on commercializing silicon nitride-based medical products including the FDA-cleared SiNAPTIC Foot & Ankle Implant System to drive revenue growth.
Stated as a priority in 2 of last 2 quarters. Revenue increased from $380,000 in 2026-Q1 to $452,000 in 2026-Q2. Guidance for 2026-Q3 projects revenue between $900,000 and $1.1 million. Management is delivering revenue growth consistent with advancing commercialization efforts.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Focus our resources on the commercialization of our silicon nitride technologies and execution of our growth strategy.”
“The Company intends to use net proceeds for commercialization activities and business development initiatives.”
Continue raising capital via private placements and at-the-market offerings to strengthen the balance sheet and fund operations.
Stated as a priority in 2 of last 2 quarters. The company raised approximately $5.0 million in equity capital through private placement and ATM offerings by 2026-Q2. This capital raise aligns with management's stated objective to strengthen the balance sheet and fund operations, showing delivery on this priority.
“Raised approximately $5.0 million of equity capital in recent weeks through private placement and ATM offering.”
“Entered into securities purchase agreements for private placement to raise capital.”
Establish a Strategic Opportunity Management Program to identify and pursue partnerships, licensing, and corporate development initiatives.
Newly stated in 2026-Q3. Management announced engagement of Southern Metrics to establish a Strategic Opportunity Management Program to evaluate partnerships and corporate development. No direct financial impact yet visible in reported results, indicating early stage of this initiative.
Focus on managing operating expenses and improving efficiency to reduce losses and improve operating income.
Stated as a priority in 2 of last 2 quarters. Operating income improved from -$3.21 million in 2026-Q1 to -$2.89 million in 2026-Q2, indicating some progress in cost management. Management's statements imply ongoing focus on strengthening operations, showing limited but positive delivery.
“Focus our resources on strengthening the company and executing our growth strategy.”
“Use of proceeds includes general corporate purposes, implying cost and operational management.”
Grow the industrial ceramics segment and diversify revenue streams beyond medical products.
Newly stated in 2026-Q2. Management expressed focus on expanding the industrial ceramics business and distribution network to support revenue growth. No distinct financial segment data available to assess progress, indicating early stage with limited delivery so far.
“The Company remains focused on expanding its distribution network and other advanced ceramics opportunities.”
Over the trailing year it converted 1.16x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
23 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.